AM-919 explained

AM-919 (part of the AM cannabinoid series) is an analgesic drug which is a cannabinoid receptor agonist. It is a derivative of HU-210 which has been substituted with a 6β-(3-hydroxypropyl) group. This adds a "southern" aliphatic hydroxyl group to the molecule as seen in the CP-series of nonclassical cannabinoid drugs, and so AM-919 represents a hybrid structure between the classical dibenzopyran and nonclassical cannabinoid families.^[1]

AM-919 is somewhat less potent than HU-210 itself, but is still a potent agonist at both CB₁ and CB₂ with moderate selectivity for CB₁, with a K_i of 2.2 nM at CB₁ and 3.4 nM at CB₂.^{[2] [3]}

See also

• AM-4030

Notes and References

1. Book: Pertwee, Roger . vanc . Cannabinoids . Handbook of Experimental Pharmacology . 168 . 269 . Springer . 3-540-22565-X .
2. Tius MA, Hill WA, Zou XL, Busch-Petersen J, Kawakami JK, Fernandez-Garcia MC, Drake DJ, Abadji V, Makriyannis A . 6 . Classical/non-classical cannabinoid hybrids; stereochemical requirements for the southern hydroxyalkyl chain . Life Sciences . 56 . 23–24 . 2007–12 . 1995 . 7776825 . 10.1016/0024-3205(95)00182-6 .
3. Drake DJ, Jensen RS, Busch-Petersen J, Kawakami JK, Concepcion Fernandez-Garcia M, Fan P, Makriyannis A, Tius MA . Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized C-6beta methyl, ethyl, and propyl analogues . Journal of Medicinal Chemistry . 41 . 19 . 3596–608 . September 1998 . 9733485 . 10.1021/jm960677q . Alexandros Makriyannis .